Tiffany Randolph, MD
Cardiovascular Disease · Greensboro, NCNPI 1861636300
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.0%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 67.0% of it on its own, with 38 other manufacturers making up the rest. Among cardiovascular disease clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 411 payments — averaging $322.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$89K
- Edwards Lifesciences$32K
- Recor Medical Inc$7K
- Amgen$1K
- Heartflow, Inc.$377
- Novartis$367
- plus $3K from 33 others
Across 23 payments — averaging $2358.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$38K
- Regeneron$14K
- Recor Medical Inc$2K
What the payments were for
- Consulting fees$71,69154%
- Speaking & faculty fees$24,70019%
- Travel & lodging$29,05022%
- Food & beverage$7,2435%
- Education$660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 153 | $88,974 |
| Edwards Lifesciences | 17 | $31,705 |
| Recor Medical Inc | 12 | $7,259 |
| Amgen | 58 | $1,091 |
| Heartflow, Inc. | 3 | $377 |
| Novartis | 22 | $367 |
| Novo Nordisk | 9 | $261 |
| Irhythm Technologies, Inc. | 10 | $257 |
| Boehringer Ingelheim | 15 | $256 |
| Bayer | 15 | $247 |
| Esperion Therapeutics, Inc. | 8 | $240 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $199 |
| Pfizer | 10 | $184 |
| AstraZeneca | 11 | $158 |
| Boston Scientific | 3 | $147 |
| Johnson & Johnson | 9 | $137 |
| E.r. Squibb & Sons, L.L.C. | 6 | $91 |
| Sanofi-aventis U.S. LLC | 5 | $82 |
| Chiesi USA, Inc. | 1 | $78 |
| Merck | 5 | $67 |
| Alnylam Pharmaceuticals Inc. | 3 | $60 |
| Lundbeck LLC | 3 | $53 |
| Cvrx, Inc. | 3 | $53 |
| Idorsia Pharmaceuticals US Inc | 1 | $52 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $44 |
| Amarin Pharma, Inc. | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 2 | $34 |
| Lilly USA, LLC | 2 | $29 |
| Abiomed | 1 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $25 |
| Portola Pharmaceuticals, LLC | 1 | $23 |
| Impulse Dynamics (USA) Inc. | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Biotronik Inc. | 1 | $14 |
| Amryt Pharma Holdings Ltd | 1 | $14 |
| Abbott | 1 | $13 |
| Cardiovascular Systems Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$132,751 in reported general payments places this provider in the 95th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 313 | $320,184 |
| Repatha SureclickEvolocumab | 219 | $215,354 |
| XareltoRivaroxaban | 102 | $89,723 |
| EntrestoSacubitril/Valsartan | 79 | $80,114 |
| FarxigaDapagliflozin Propanediol | 66 | $69,212 |
| OzempicSemaglutide | 43 | $43,952 |
| JardianceEmpagliflozin | 31 | $37,141 |
| Praluent PenAlirocumab | 41 | $20,082 |
| WegovySemaglutide | 12 | $18,469 |
| VascepaIcosapent Ethyl | 19 | $9,122 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $5,487 |
| Valsartan | 213 | $5,153 |
| Metoprolol Succinate | 290 | $4,331 |
| Nebivolol Hcl | 51 | $4,141 |
| Rosuvastatin Calcium | 373 | $3,951 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $184 | $320,184313 claims |
| Johnson & JohnsonXarelto | $137 | $89,723102 claims |
| NovartisEntresto | $367 | $80,11479 claims |
| AstraZenecaFarxiga | $158 | $69,21266 claims |
| Novo NordiskOzempic, Wegovy | $261 | $62,42155 claims |
| Boehringer IngelheimJardiance | $256 | $37,14131 claims |
| Esperion Therapeutics, Inc.Nexlizet | $240 | $5,48712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 727 cardiovascular disease providers in North Carolina.
Other cardiovascular disease in Greensboro
- Cameron LambertGreensboro$99K
- Wesley O'NealGreensboro$85K
- Kenneth HiltyGreensboro$51K
- Katarina NelsonGreensboro$46K
- R WilliamsDurham$2.1M
- Marat FudimDurham$902K
- Jonathan PicciniDurham$767K
- Michael RinaldiCharlotte$722K
- Markus SchererCharlotte$526K
- Robert MentzDurham$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.